University of Iowa
497
65
94
304
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
13.9%
69 terminated/withdrawn out of 497 trials
81.5%
-5.1% vs industry average
11%
57 trials in Phase 3/4
52%
157 of 304 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (497)
CALM IVF (Creating Affiliations, Learning, and Mindfulness for In Vitro Fertilization Patients)
Role: lead
Parasitic Ulcer Treatment Trial
Role: collaborator
Behavioral Economic & Staffing Strategies in the ICU
Role: collaborator
Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance
Role: collaborator
Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis.
Role: lead
SAIL-MEVO: Endovascular Treatment Versus Best Medical Therapy for Distal Vessel Occlusions
Role: collaborator
BEGIN Novel ImagiNG Biomarkers
Role: collaborator
Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)
Role: collaborator
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
Role: collaborator
Randomized Trial on Mobile Technology and Young Drivers' Cellphone Use
Role: collaborator
Sinus Disease in Young Children With Cystic Fibrosis
Role: collaborator
Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis
Role: lead
Dimensional Changes: Randomized Clinical Trial
Role: lead
Healing Dynamics in Human Extraction Sockets Grafted With Bio-Oss Collagen®
Role: lead
Antibiotic Irrigations for Intra-Abdominal Drains
Role: lead
Pharmacist Intervention to Improve Smoking Cessation
Role: lead
Dime La VerDAD: Verify, Debunk, and Disseminate
Role: collaborator
PERceptions of Diltiazem Versus ADEnosine for Treatment of Supraventricular Tachycardia in the Emergency Department
Role: lead
Neuroendocrine Tumors - Patient Reported Outcomes
Role: lead
Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy
Role: collaborator